貨號：GS40148

Coramitug (formerly PRX004) is an investigational humanized monoclonal antibody developed by Novo Nordisk (from Prothena) for treating Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM), a heart condition where misfolded TTR protein builds up as amyloid. It works by clearing these harmful TTR amyloid deposits, showing promise in reducing disease markers like NT-proBNP in Phase 2 trials and advancing to Phase 3 (CLEOPATTRA study) to assess its impact on heart failure.